Fairmount Funds Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $85.1M | Hold |
815,176
| – | – | 11.02% | 2 |
|
|
2025
Q1 | $95.1M | Sell |
815,176
-653,807
| -45% | -$76.3M | 14.75% | 1 |
|
|
2024
Q4 | $124M | Sell |
1,468,983
-891,094
| -38% | -$75.4M | 12.36% | 1 |
|
|
2024
Q3 | $212M | Hold |
2,360,077
| – | – | 17.2% | 1 |
|
|
2024
Q2 | $190M | Hold |
2,360,077
| – | – | 21.46% | 1 |
|
|
2024
Q1 | $188M | Hold |
2,360,077
| – | – | 20.53% | 1 |
|
|
2023
Q4 | $188M | Buy |
2,360,077
+18,839
| +0.8% | +$1.5M | 19.85% | 1 |
|
|
2023
Q3 | $164M | Sell |
2,341,238
-3,742
| -0.2% | -$262K | 19.69% | 1 |
|
|
2023
Q2 | $169M | Buy |
2,344,980
+333,333
| +17% | +$24M | 23.76% | 1 |
|
|
2023
Q1 | $124M | Hold |
2,011,647
| – | – | 21.34% | 1 |
|
|
2022
Q4 | $155M | Buy |
2,011,647
+115,000
| +6% | +$8.87M | 24.61% | 1 |
|
|
2022
Q3 | $84.6M | Buy |
1,896,647
+954,076
| +101% | +$42.6M | 14.88% | 1 |
|
|
2022
Q2 | $36.1M | Hold |
942,571
| – | – | 8.26% | 2 |
|
|
2022
Q1 | $39M | Buy |
942,571
+754,973
| +402% | +$31.2M | 9.22% | 4 |
|
|
2021
Q4 | $7.09M | Hold |
187,598
| – | – | 2.34% | 17 |
|
|
2021
Q3 | $6.18M | Sell |
187,598
-125,000
| -40% | -$4.12M | 2.25% | 18 |
|
|
2021
Q2 | $21.1M | Buy |
312,598
+61,000
| +24% | +$4.12M | 8.67% | 3 |
|
|
2021
Q1 | $14.2M | Buy |
251,598
+31,500
| +14% | +$1.78M | 6% | 5 |
|
|
2020
Q4 | $17.9M | Hold |
220,098
| – | – | 6.41% | 8 |
|
|
2020
Q3 | $15.7M | Buy |
220,098
+4,000
| +2% | +$285K | 6.64% | 7 |
|
|
2020
Q2 | $17.8M | Buy |
216,098
+26,500
| +14% | +$2.18M | 7.93% | 5 |
|
|
2020
Q1 | $11.2M | Buy |
+189,598
| New | +$11.2M | 6.76% | 6 |
|